Enoda, a healthtech startup, has announced the launch of a novel platform to deliver real-world mobility data to global pharmaceutical, medtech and clinical research partners. The data will enable them to gain unprecedented insight into how their therapies impact patient mobility in everyday life.
For millions of patients with conditions like Parkinson’s, MS, and COPD, mobility is a vital aspect of health. However, drug development has historically been slowed by the lack of measurement tools that can assess mobility accurately in real-world settings.
Addressing critical gap
Enoda’s novel platform, designed to meet the rigorous demands of modern clinical trials, is addressing this critical gap, empowering researchers and pharmaceutical companies with clinically meaningful, high-fidelity data to enhance patient insight and therapeutic development.
Pictured at the Cobh Enterprise Centre, Co Cork, is Michael McMahon, CEO, Enoda. Image: Enoda.
Enoda recently spun out of University College Dublin (UCD) and Newcastle University jointly with the support of NovaUCD and Newcastle Innovations and is an Enterprise Ireland High-Potential Start-Up (HPSU) company.
The company has emerged from research led by Professor Lynn Rochester, Translational and Clinical Research Institute and colleagues at Newcastle University and by Professor Brian Caulfield, UCD School of Public Health, Physiotherapy and Sports Science and colleagues at UCD, as part of Mobilise-D.
Mobilise-D, a five-year €50m pan-European project which concluded in 2024, was funded by the Innovative Medicines Initiative (IMI) with the focus of transforming how mobility loss is measured in people with chronic conditions such as Parkinson’s, MS, and COPD.
The technology has been robustly validated in a technical validation study with c.100 participants across six cohorts and a clinical validation study with 2,366 participants across four disease cohorts, as part of Mobilise-D.
“The launch of Enoda as an independent spin-out from UCD and Newcastle University marks a pivotal moment for clinical research and will realise the many benefits real-world mobility data can bring to drug development,” said, Michael McMahon, CEO, Enoda.
“By transforming the groundbreaking €50m Mobilise-D research into a fully realised, customer-ready Electronic Data Capture platform, we are giving pharma and medtech companies the tools they need to capture accurate and meaningful mobility data.”
Assessment of mobility in chronic conditions
“For years, the assessment of mobility in chronic conditions was limited by subjective or insensitive clinical tests,” said Professor Lynn Rochester, Newcastle University and a co-founder of Enoda.
“Seeing the scientific breakthroughs of the Mobilise-D consortium evolve into a robust, accessible commercial platform through Enoda ensures that our research will have a direct, lasting impact on global drug development and, ultimately, patient care.”
Professor Brian Caulfield, UCD School of Public Health, Physiotherapy and Sports Science and a co-founder of Enoda, said: “Translating the complex, validated data pipelines developed during the €50m Mobilise-D project into a scalable commercial architecture was a critical hurdle in modernising clinical trials. Through Enoda, we have established a secure Electronic Data Capture platform that allows pharmaceutical and clinical research partners to integrate validated digital mobility outcomes directly into their workflows, ensuring absolute confidence in data integrity and patient monitoring.
“We are incredibly grateful to NovaUCD and Newcastle Innovations for the supported received and for the backing of Enterprise Ireland as an HPSU which significantly accelerates our mission to deploy this vital technology to the global market.”
Enoda is currently based at the Cobh Enterprise Centre in Co Cork.
